Home » Newsletters » BioWorld

BioWorld

Dec. 23, 1991

View Archived Issues

BTGC GROSSES $13 MILLION IN STOCK SALE

APPOINTMENTS AND ADVANCEMENTS

DYNAGEN LICENSES TB ANTIBODIES

CHIEF SCIENTIFIC OFFICER LEAVES LIDAK

IDEXX RENEGOTIATES ACQUISITION

ANALYST REDUCES RATING ON BIOGEN

ONCOGENE RAISES $17.1 MILLION IN OFFERING

VIMRX FILES FOR OFFERING

IMMULOGIC FILES FOR 2 MILLION-SHARE OFFERING

CORVAS FILES FOR 2.5 MILLION-SHARE IPO

FDA TO REVIEW CHIRON, CYTOGEN PRODUCTS

COURT SMOTHERS NICODERM INJUNCTION

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...